Sun Pharma’s India growth and launches offset US generics weakness in Q1FY27
Sun Pharma reported 10% year-on-year consolidated revenue growth in Q1FY27, driven by a 16% rise in India formulations revenue and five domestic product launches. Innovative medicines and emerging markets also grew, while US formulations fell 9.7%. Its Organon acquisition is expected to close in Q4FY27.
Sun Pharma’s Q1FY27 revenue rose 10%, led by 16% growth in India formulations and five domestic launches, including generic injectable semaglutide. US generics declined, while innovative medicines grew. Organon acquisition is expected to close in Q4FY27.
Why this matters
The result follows Sun Pharma's Q1 earnings miss tied to a 9.7% US generics decline, while recent voluntary eye-drop recalls and halted distributor sales add scrutiny to its India operations.
Retail-company is accelerating, up 202,443% QoQ.